MedTrace Logo

AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours

NCT00704366 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2011-05-16

No results posted yet for this study

Summary

This is a dose escalation study to assess the safety and tolerability of AZD0530 in patients with advanced solid malignancies.

Conditions

Interventions

DRUG

AZD0530

oral, tablet, once daily, dose will be variable

Sponsors & Collaborators

Principal Investigators

  • Mary Stuart, MD · AstraZeneca

  • Narikazu Boku, MD · Saint Marianna University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2011-01-31
Completion
2011-05-31

Countries

  • Japan

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00704366 on ClinicalTrials.gov